Promotional Tone in Reviews of Menopausal Hormone Therapy After the Women's Health Initiative: An Analysis of Published Articles

English version České info

Background:
Even after the Women's Health Initiative (WHI) found that the risks of menopausal hormone therapy (hormone therapy) outweighed benefit for asymptomatic women, about half of gynecologists in the United States continued to believe that hormones benefited women's health. The pharmaceutical industry has supported publication of articles in medical journals for marketing purposes. It is unknown whether author relationships with industry affect promotional tone in articles on hormone therapy. The goal of this study was to determine whether promotional tone could be identified in narrative review articles regarding menopausal hormone therapy and whether articles identified as promotional were more likely to have been authored by those with conflicts of interest with manufacturers of menopausal hormone therapy.

Methods and Findings:
We analyzed tone in opinion pieces on hormone therapy published in the four years after the estrogen-progestin arm of the WHI was stopped. First, we identified the ten authors with four or more MEDLINE-indexed reviews, editorials, comments, or letters on hormone replacement therapy or menopausal hormone therapy published between July 2002 and June 2006. Next, we conducted an additional search using the names of these authors to identify other relevant articles. Finally, after author names and affiliations were removed, 50 articles were evaluated by three readers for scientific accuracy and for tone. Scientific accuracy was assessed based on whether or not the findings of the WHI were accurately reported using two criteria: (1) Acknowledgment or lack of denial of the risk of breast cancer diagnosis associated with hormone therapy, and (2) acknowledgment that hormone therapy did not benefit cardiovascular disease endpoints. Determination of promotional tone was based on the assessment by each reader of whether the article appeared to promote hormone therapy. Analysis of inter-rater consistency found moderate agreement for scientific accuracy (κ = 0.57) and substantial agreement for promotional tone (κ = 0.65). After discussion, readers found 86% of the articles to be scientifically accurate and 64% to be promotional in tone. Themes that were common in articles considered promotional included attacks on the methodology of the WHI, arguments that clinical trial results should not guide treatment for individuals, and arguments that observational studies are as good as or better than randomized clinical trials for guiding clinical decisions. The promotional articles we identified also implied that the risks associated with hormone therapy have been exaggerated and that the benefits of hormone therapy have been or will be proven. Of the ten authors studied, eight were found to have declared payment for speaking or consulting on behalf of menopausal hormone manufacturers or for research support (seven of these eight were speakers or consultants). Thirty of 32 articles (90%) evaluated as promoting hormone therapy were authored by those with potential financial conflicts of interest, compared to 11 of 18 articles (61%) by those without such conflicts (p = 0.0025). Articles promoting the use of menopausal hormone therapy were 2.41 times (95% confidence interval 1.49–4.93) as likely to have been authored by authors with conflicts of interest as by authors without conflicts of interest. In articles from three authors with conflicts of interest some of the same text was repeated word-for-word in different articles.

Conclusion:
There may be a connection between receiving industry funding for speaking, consulting, or research and the publication of promotional opinion pieces on menopausal hormone therapy.

: Please see later in the article for the Editors' Summary

Vyšlo v časopise: Promotional Tone in Reviews of Menopausal Hormone Therapy After the Women's Health Initiative: An Analysis of Published Articles. PLoS Med 8(3): e32767. doi:10.1371/journal.pmed.1000425
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.pmed.1000425

Souhrn

Zdroje

1. PowerML

SchulkinJ

RossouwJE

2007 Evolving practice patterns and attitudes toward hormone therapy of obstetrician-gynecologists. Menopause 14 20 28

2. PowerML

BaronJ

SchulkinJ

2008 Factors associated with obstetrician-gynecologists' response to the Women's Health Initiative trial of combined hormone therapy. Med Decis Making 28 411 418

3. PowerML

AndersonBL

SchulkinJ

2009 Attitudes of obstetrician-gynecologists toward the evidence from the Women's Health Initiative hormone therapy trials remain generally skeptical. Menopause 16 500 508

4. RossouwJE

AndersonGL

PrenticeRL

LaCroixAZ

KooperbergC

2002 Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial. JAMA 288 321 333

5. The Women's Health Initiative Steering C 2004 Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: The Women's Health Initiative randomized controlled trial. JAMA 291 1701 1712

6. ShumakerSA

LegaultC

KullerL

RappSR

ThalL

2004 Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study. JAMA 291 2947 58

7. HendrixSL

CochraneBB

NygaardIE

HandaVL

BarnabeiVM

2005 Effects of estrogen with and without progestin on urinary incontinence. JAMA 293 935 48

8. HaysJ

OckeneJK

BrunnerRL

KotchenJM

MansonJE

2003 Effects of estrogen plus progestin on health-related quality of life. N Engl J Med 348 1839 1854

9. BrunnerRL

GassM

AragakiA

HaysJ

GranekI

2005 Effects of conjugated equine estrogen on health-related quality of life in postmenopausal women with hysterectomy: Results from the Women's Health Initiative randomized clinical trial. Arch Intern Med 165 1976 1986

10. MajumdarSR

AlmasiEA

StaffordRS

2004 Promotion and prescribing of hormone therapy after report of harm by the Women's Health Initiative. JAMA 292 1983 1988

11. RavdinPM

CroninKA

HowladerN

BergCD

ChlebowskiRT

2007 The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med 356 1670 1674

12. ChlebowskiRT

KullerLH

PrenticeRL

StefanickML

MansonJE

2009 Breast cancer after use of estrogen plus progestin in postmenopausal women. N Engl J Med 360 573 587

13. ChlebowskiRT

AndersonGL

GassM

LaneDS

AragakiAK

2010 Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA 304 1684 1692

14. StaffordRS

SaglamD

CausinoN

BlumenthalD

1997 Low rates of hormone replacement in visits to United States primary care physicians. Am J Obstet Gynecol 177 381 387

15. SaverBG

TaylorTR

WoodsNF

StevensNG

1997 Physician policies on the use of preventive hormone therapy. Am J Prev Med 13 358 365

16. BrettAS

CarneyPI

McKeownRE

2005 Brief report: Attitudes toward hormone therapy after the Women's Health Initiative: a comparison of internists and gynecologists. J Gen Intern Med 20 416 418

17. SpanglerL

ReedSD

NekhyludovL

GrothausLC

LaCroixAZ

2009 Provider attributes associated with hormone therapy prescribing frequency. Menopause 16 810 816

18. HershAL

StefanickML

StaffordRS

2004 National use of postmenopausal hormone therapy: Annual trends and response to recent evidence. JAMA 291 47 53

19. Fugh-BermanA

ScialliAR

2006 Gynecologists and estrogen: An affair of the heart. Perspect Biol Med 49 115 130

20. SingerN

2009 August 4 Medical papers by ghostwriters pushed therapy. The New York Times Available: http://www.nytimes.com/2009/08/05/health/research/05ghost.html. Accessed 4 Aug 2009

21. RossJS

HillKP

EgilmanDS

KrumholzHM

2008 Guest authorship and ghostwriting in publications related to rofecoxib. JAMA 299 1800 1812

22. SteinmanMA

BeroLA

ChrenM

LandefeldCS

2006 Narrative review: the promotion of gabapentin: an analysis of internal industry documents. Ann Intern Med 145 284 293

23. HealyD

CattelD

2003 Interface between authorship, industry, and science in the domain of therapeutics. Brit J Psych 183 22 27

24. Fugh-BermanA

MelnickD

2008 Off-label promotion, on-target sales. PLoS Med 5 e210 doi:10.1371/journal.pmed.0050210

25. FauberJ

RustS

2009 January 25 UW course for doctors pushed risky therapy. Milwaukee Journal Sentinel Available: http://www.jsonline.com/features/health/38283649.html. Accessed 5 February 2011

26. FauberJ

KissingerM

2009 August 15 UW linked to ghostwriting. Milwaukee Journal Sentinel Available: http://www.jsonline.com/features/health/53315032.html. Accessed 5 February 2011

27. Publication Program Drug Industry Document Archive. Available: http://dida.library.ucsf.edu/tid/kjb37b10. Accessed 20 November 2010

28. Publication Program A Proposal for Wyeth-Ayerst Pharmaceuticals - Council on Hormone Education, Scientific Update on Hormones and Postmenopausal Health. Available: http://dida.library.ucsf.edu/tid/iyb37b10. Accessed 20 November 2010

29. RandolphJJ

2008 Online kappa calculator. Available: http://justus.randolph.name/kappa. Accessed 26 August 2009

30. LexchinJ

BeroLA

DjulbegovicB

ClarkO

2003 Pharmaceutical industry sponsorship and research outcome and quality: Systematic review. BMJ 326 1167 1170

31. JørgensenAW

HildenJ

GøtzschePC

2006 Cochrane reviews compared with industry supported meta-analyses and other meta-analyses of the same drugs: Systematic review. BMJ 333 782

32. JørgensenAW

MaricKL

TendalB

FaurschouA

GøtzschePC

2008 Industry-supported meta-analyses compared with meta-analyses with non-profit or no support: differences in methodological quality and conclusions. BMC Med Res Methodol 8 60

33. CosgroveL

BursztajnHJ

KrimskyS

AnayaM

WalkerJ

2009 Conflicts of interest and disclosure in the American Psychiatric Association's Clinical Practice Guidelines. Psychother Psychosom 78 228 232

34. RoseJ

2008 Industry influence in the creation of pay-for-performance quality measures. Qual Manag Health Care 17 27 34

35. HemminkiE

2003 Opposition to unpopular research results: Finnish professional reactions to the WHI findings. Health Policy 69 283 291

36. PrenticeRL

ChlebowskiRT

StefanickML

MansonJE

PettingerM

2008 Estrogen plus progestin therapy and breast cancer in recently postmenopausal women. Am J Epidemiol 167 1207 1216

37. American College of Cardiology ACCEL: ACCF's Disclosure/conflict of interest policy. Available: http://stage.acc.org/accel_disclosures.htm. Accessed November 26, 2010

38. BushTM

BonomiAE

NekhlyudovL

LudmanEJ

ReedSD

2007 How the Women's Health Initiative (WHI) influenced physicians' practice and attitudes. J Gen Intern Med 22 1311 1316

39. StelfoxHT

ChuaG

O'RourkeK

DetskyAS

1998 Conflict of interest in the debate over calcium-channel antagonists. N Engl J Med 338 101 106

40. TatsioniA

SiontisGCM

IoannidisJPA

2010 Partisan perspectives in the medical literature: A study of high frequency editorialists favoring hormone replacement therapy. J Gen Int Med 25 914 919

41. MathesonA

2008 Corporate science and the husbandry of scientific and medical knowledge by the pharmaceutical industry. BioSocieties 3 355 382

42. GlinertLH

2005 TV commercials for prescription drugs: a discourse analytic perspective. Res Social Admin Pharm 1 158 184

43. [No authors listed] 2009 Self-plagiarism: Unintentional, harmless, or fraud? Lancet 374 664

44. PLoS Medicine 2009 Ghostwriting: The dirty little secret of medical publishing that just got bigger. Available: http://www.plosmedicine.org/article/info%3Adoi%2F10.1371%2Fjournal.pmed.1000156. Accessed 12 February 2011

45. Fugh-BermanAJ

2010 The haunting of medical journals: How ghostwriting sold “HRT”. PLoS Med 7 e1000335 doi:10.1371/journal.pmed.1000335

46. Draft of Low-Dose Review Paper [With Annotations] DWRITE073011. Prempro Products Liability Litigation, MDL Docket No 4:03CV1507 WRW (W.D. Arkansas). Available: http://dida.library.ucsf.edu/tid/qlc37b10. Accessed 26 November 2010

47. Low-dose Review Paper Submitted to Climacteric DWRITE73106. Prempro Products Liability Litigation, MDL Docket No 4:03CV1507 WRW (W.D. Arkansas). Available: http://dida.library.ucsf.edu/tid/qnb37b10. Accessed 26 November 2010

48. Response Letter to Alastair MacLennan Prempro Products Liability Litigation, MDL Docket No 4:03CV1507 WRW (W.D. Arkansas). DWRITE072945. Available: http://dida.library.ucsf.edu/tid/qib37b10. Accessed 26 November 2010

49. Draft of metabolic paperDELCA032-028548 Prempro Products Liability Litigation, MDL Docket No 4:03CV1507 WRW (W.D. Arkansas). Available: http://dida.library.ucsf.edu/tid/czb37b10. Accessed 26 November 2010

50. Effects of Lower Doses of Conjugated Estrogens and Medroxyprogesterone Acetate on Plasma Lipids and Lipoproteins, Coagulation Factors, and Carbohydrate Metabolism Prempro Products Liability Litigation, MDL Docket No 4:03CV1507 WRW (W.D. Arkansas). DELCA032-028549. Available: http://dida.library.ucsf.edu/tid/czc37b10. Accessed 26 November 2010

51. Inconsistency in Epidemiological Findings on Postmenopausal Hormone Therapy and Breast Cancer DWRITE078512. (Exh. 96 to Janas Depos.) Prempro Products Liability Litigation, MDL Docket No 4:03CV1507 WRW (W.D. Arkansas). Available: http://dida.library.ucsf.edu/tid/rrb37b10. Accessed 26 November 2010

52. Re: Draft of Manuscript DWRITE078370. (Exh. 95 to Janas Depos.) Prempro Products Liability Litigation, MDL Docket No 4:03CV1507 WRW (W.D. Arkansas). Available: http://dida.library.ucsf.edu/tid/rqc37b10. Accessed 26 November 2010

53. Janas Deposition: 483:1l–485:13 Prempro Products Liability Litigation, MDL Docket No 4:03CV1507 WRW (W.D. Arkansas). Available: http://dida.library.ucsf.edu/pdf/skc37b10. Accessed 26 November 2010

54. Endometrial paper and action steps from last meeting DELCA031-019050 Prempro Products Liability Litigation, MDL Docket No 4:03CV1507 WRW (W.D. Arkansas). Available: http://dida.library.ucsf.edu/search?query=DELCA031-019050&ct=1. Accessed 26 November 2010

55. Endometrial Effects of Lower Doses of Conjugated Equine Estrogens and Medroxyprogesterone Acetate DELCA031-019052. Prempro Products Liability Litigation, MDL Docket No 4:03CV1507 WRW (W.D. Arkansas). Available: http://dida.library.ucsf.edu/pdf/cvc37b10. Accessed 26 November 2010